Given that the US undertakes historic adjustments to its immunization recommendations, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by casting doubt on coronavirus shots during the pandemic and has zeroed in on possible deaths after Covid immunization in her short time at the US Food and Drug Administration (FDA).
Health officials had intended to announce sweeping revisions to the childhood vaccination calendar in December, synchronizing the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US at odds with much of the global community with no evidence for public health gain. The announcement has been delayed until the next year.
In place of the director of the vaccine center, Dr. Høeg is listed to speak at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this year.
This interim role might represent a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a renewed priority upon reevaluating previously authorized vaccines at the FDA.
Dr. Høeg has frequently advocated for halting some pediatric vaccine recommendations in the US to become more similar to Denmark, a nation with nationalized medicine and a number of inhabitants approximately the size of Wisconsin’s.
To date public appearances, she has continued to focus on vaccines – traditionally the purview of Dr. Prasad, director of the FDA’s CBER – instead of drug regulation.
Høeg has no obvious experience in drug development, oversight or administrative roles, which has been typical for former directors of the CBER. She has been employed at the FDA as a senior adviser to the agency head and CBER since earlier this year.
“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in running a large organization. She lacks background in pharmaceutical oversight.”
Previous heads of CBER would “understand laws and regulations and the science of drug development”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that prior appointees who ran CBER have had.”
CDER has an immense portfolio at the agency, Woodcock pointed out.
“The public just focuses on the new drug program, but the generic program approves thousands of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and so forth, and each of these must be looked after,” Dr. Woodcock noted. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”
Furthermore, a substantial management element to the job, which oversees over 5,000 personnel. “It’s a enormous management job, if you do it right,” she added.
When asked about questions about Høeg’s qualifications and whether this assignment indicates greater collaboration among agency officials on vaccines, a spokesperson responded that the “inquiries rely on inaccurate assumptions”.
“This background aligns with the duties of her role,” the representative stated, noting the time Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computational safety modeling and shot safety tracking”.
As the temporary head, Høeg takes over the agency head's recently launched expedited review system, a controversial expedited therapy clearance system that apparently troubled her preceding directors. “How are these drugs being picked for this expedited pathway? Who makes the choices?” Howard questioned. “There is a lot of secrecy occurring at the regulatory body right now.”
Overall, he stated, “the agency looks to be trending towards more relaxed oversight of most medications, aside from vaccines.”
Concerning vaccines, Høeg has a more established, if concerning, past, Howard observe. She authored a analysis using unconfirmed public submissions to determine the incidence of myocarditis after Covid immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are more dangerous than they are.
Included in her “wish list” for the current federal leadership included altering guidelines for new vaccines and halting “unnecessary” vaccines, she stated post-election on a podcast. At the agency, Dr. Høeg has according to sources suggested barring teenage boys from obtaining COVID-19 vaccines.
“She’s an complete true believer who commences with her conclusions and works backwards to retrofit the science in a extremely disingenuous, dishonest manner,” Howard stated.
Dr. Høeg joined fellow contrarians, {like|
News